Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia.
Cancer cachexia is a wasting condition, driven by systemic inflammation and oxidative stress. This study investigated eicosapentaenoic acid (EPA) in combination with oxypurinol as a treatment in a mouse model of cancer cachexia. Mice with cancer cachexia were randomized into 4 treatment groups (EPA...
Main Authors: | Vanessa C Vaughan, Melanie Sullivan-Gunn, Edward Hinch, Peter Martin, Paul A Lewandowski |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3447801?pdf=render |
Similar Items
-
EICOSAPENTAENOIC ACID AS ADJUVANT FOR CACHEXIA IN CANCER’S PATIENTS
by: Soeseno Hadi, et al.
Published: (2015-03-01) -
Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate‐Lowering Response—In Search of a Minimum Effective Oxypurinol Concentration
by: Lisa K. Stamp, et al.
Published: (2020-01-01) -
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics
by: Hailemichael Z. Hishe, et al.
Published: (2023-03-01) -
Effects of eicosapentaenoic acid intake on denervation-induced mitochondrial adaptation in mouse skeletal muscle
by: Kohei Takeda, et al.
Published: (2018-09-01) -
Mathematical Model of Muscle Wasting in Cancer Cachexia
by: Suzan Farhang-Sardroodi, et al.
Published: (2020-06-01)